What after Amit Sachdev’s Insider Unload of Vertex Pharmaceuticals (VRTX) Stock?; Ultra Clean Holdings (UCTT) Sentiment Is 1.32

January 24, 2018 - By John Hoffman

Ultra Clean Holdings, Inc. designs, develops, prototypes, engineers, makes, and tests production tools, modules, and subsystems for the semiconductor capital equipment and equipment industry divisions primarily in North America, Asia, and Europe. The company has market cap of $851.48 million. It offers precision robotic systems that are used when accurate controlled motion is required; gas delivery systems, which include one or more gas lines consisting of small diameter internally polished stainless steel tubing products, filters, mass flow controllers, regulators, pressure transducers and valves, component heaters, and an integrated electronic and/or pneumatic control system; and various industrial and automation production equipment products. It has a 13.47 P/E ratio. The firm also provides subsystems, such as wafer cleaning sub-systems; chemical delivery modules that deliver gases and reactive chemicals in a liquid or gaseous form from a centralized subsystem to the reaction chamber; frame assemblies, which are support structures fabricated from steel tubing or folded sheet metal; and top-plate assemblies.

Amit Sachdev; that is an insider in Vertex Pharmaceuticals Inc Ma who is the most recent to unload shares in the company for which he is presently the EVP – CRO. He in the last few days sold some 46,172 shares of the company, valued by the market at around $7,325,400 USD, that is a price for each share of about $158.7. The trade was huge and not likely to stay undiscovered. Amit Sachdev at the moment has rights to 0.02% of the Company’s stock market capitalization with ownership of 52,260 shares.  The transaction was dated 23-01-2018 and was revealed in a document filed with the Washington-based SEC. The document is on hand here.

Ratings analysis reveals 67% of Ultra Clean Holdings’s analysts are positive. Out of 3 Wall Street analysts rating Ultra Clean Holdings, 2 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $9.5 while the high is $10.0. The stock’s average target of $9.75 is -61.54% below today’s ($25.35) share price. UCTT was included in 3 notes of analysts from October 25, 2016. The stock of Ultra Clean Holdings, Inc. (NASDAQ:UCTT) earned “Buy” rating by Dougherty & Company on Tuesday, October 25. The stock has “Buy” rating by Needham on Thursday, October 27. The firm earned “Hold” rating on Tuesday, November 15 by Standpoint Research.

Since January 1, 0001, it had 0 buys, and 6 sales for $1.92 million activity.

Analysts await Ultra Clean Holdings, Inc. (NASDAQ:UCTT) to report earnings on February, 28. They expect $0.60 EPS, up 66.67% or $0.24 from last year’s $0.36 per share. UCTT’s profit will be $20.15 million for 10.56 P/E if the $0.60 EPS becomes a reality. After $0.62 actual EPS reported by Ultra Clean Holdings, Inc. for the previous quarter, Wall Street now forecasts -3.23% negative EPS growth.

The stock decreased 0.86% or $0.22 during the last trading session, reaching $25.35. About 1.49 million shares traded or 1.27% up from the average. Ultra Clean Holdings, Inc. (UCTT) has risen 320.86% since January 24, 2017 and is uptrending. It has outperformed by 304.16% the S&P500.

Awm Investment Company Inc. holds 3.99% of its portfolio in Ultra Clean Holdings, Inc. for 746,716 shares. Zpr Investment Management owns 79,170 shares or 3.68% of their US portfolio. Moreover, Sanctuary Wealth Advisors Llc has 2.97% invested in the company for 125,522 shares. The Oregon-based Pacific Ridge Capital Partners Llc has invested 2.14% in the stock. Smith Graham & Co. Investment Advisors Lp, a Texas-based fund reported 602,752 shares.

The stock increased 2.88% or $4.67 during the last trading session, reaching $166.58. About 3.06M shares traded or 92.74% up from the average. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 45.69% since January 24, 2017 and is uptrending. It has outperformed by 28.99% the S&P500.

Investors sentiment increased to 1.62 in 2017 Q3. Its up 0.11, from 1.51 in 2017Q2. It increased, as 32 investors sold Vertex Pharmaceuticals Incorporated shares while 151 reduced holdings. 79 funds opened positions while 217 raised stakes. 231.42 million shares or 0.04% more from 231.33 million shares in 2017Q2 were reported. Peak6 Limited Partnership has invested 0.01% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Atalanta Sosnoff Capital Limited Liability holds 2.05% or 389,601 shares. Ingalls And Snyder Limited Liability Corp owns 3,270 shares. Fiera Capital accumulated 2,104 shares or 0% of the stock. Pictet Asset Management stated it has 0.44% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). 96,854 were reported by Cullinan Associate. Glaxis Cap Mgmt Llc reported 5,000 shares stake. Gsa Ptnrs Limited Liability Partnership accumulated 17,113 shares. Shelton Management holds 0.27% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) or 23,073 shares. Northcoast Asset Mngmt Limited Liability holds 0.08% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 4,470 shares. Driehaus Cap Mngmt Ltd Liability Com owns 2,563 shares. Dupont Management invested in 0.15% or 43,402 shares. Dynamic Capital Limited has invested 0.44% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Capstone Invest Ltd Liability Company has 2,600 shares for 0.01% of their portfolio. Amalgamated National Bank has 0.14% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Since July 31, 2017, it had 0 buys, and 30 selling transactions for $90.79 million activity. 1,289 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares with value of $195,670 were sold by Silva Paul M. Shares for $324,976 were sold by Parini Michael on Thursday, October 12. $11.77M worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares were sold by Arbuckle Stuart A. $330,671 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was sold by SMITH IAN F. The insider LEIDEN JEFFREY M sold 125,000 shares worth $17.67M. ALTSHULER DAVID sold $8.83M worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Tuesday, January 16. Graney Thomas sold $116,511 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Tuesday, January 2.

Among 28 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 24 have Buy rating, 0 Sell and 4 Hold. Therefore 86% are positive. Vertex Pharmaceuticals has $205.0 highest and $85.0 lowest target. $168.73’s average target is 1.29% above currents $166.58 stock price. Vertex Pharmaceuticals had 81 analyst reports since July 31, 2015 according to SRatingsIntel. On Wednesday, July 19 the stock rating was upgraded by Barclays Capital to “Overweight”. The stock has “Mkt Perform” rating by Raymond James on Tuesday, September 13. The stock has “Outperform” rating by Cowen & Co on Wednesday, July 19. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) earned “Outperform” rating by Leerink Swann on Tuesday, March 8. On Wednesday, July 19 the stock rating was maintained by Jefferies with “Buy”. As per Friday, June 9, the company rating was maintained by Jefferies. The company was initiated on Wednesday, September 9 by Jefferies. UBS downgraded the shares of VRTX in report on Wednesday, July 19 to “Hold” rating. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) earned “Buy” rating by BMO Capital Markets on Tuesday, July 18. H.C. Wainwright maintained the stock with “Hold” rating in Thursday, October 26 report.